RenovoRx names James Ahlers CFO, Chris Lehman resigns; Ronald Kocak added as VP/Controller

RenovoRx, Inc.

CFO Christopher Lehman resigned effective July 15, 2022 to pursue a new opportunity.
James Ahlers appointed CFO, Secretary and Treasurer effective July 15, 2022; will serve as principal financial and accounting officer.
Ahlers is a consultant from Danforth Advisors; RenovoRx pays Danforth $450/hour for his services.
Ronald B. Kocak, CPA, appointed VP and Controller; previously served as interim controller since October 2021.
Ahlers has over 25 years life science finance experience, including CFO of Intarcia Therapeutics.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James Ahlers

Chief Financial Officer, Secretary and Treasurer

RNXT · RenovoRx, Inc.

Effective: 2022-07-15
Filed: July 19, 2022, 7:59 PM ET

The Company’s Board of Directors has appointed Mr. James Ahlers, age 58, as Chief Financial Officer, Secretary and Treasurer, as of July 15, 2022.

Departed

Christopher J. Lehman

Chief Financial Officer

RNXT · RenovoRx, Inc.

Effective: 2022-07-15
Successor: James Ahlers
Filed: July 19, 2022, 7:59 PM ET

Christopher J. Lehman notified RenovoRx, Inc. (the “Company”) of his decision to resign as Chief Financial Officer, effective July 15, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Ahlers was appointed as Chief Financial Officer, Secretary and Treasurer at RenovoRx, Inc..

Action: appointed
Role: Chief Financial Officer, Secretary and Treasurer

Exact text from the filing

The Company’s Board of Directors has appointed Mr. James Ahlers, age 58, as Chief Financial Officer, Secretary and Treasurer, as of July 15, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher J. Lehman resigned as Chief Financial Officer at RenovoRx, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Christopher J. Lehman notified RenovoRx, Inc. (the “Company”) of his decision to resign as Chief Financial Officer, effective July 15, 2022.

View on SEC.gov

RenovoRx, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-019760

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.